US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jul 2, 2013 (13 years ago)

CITALOPRAM Tablet

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling:Label Mixup; CITALOPRAM Tablet, 10 mg may be potentially mislabeled as OXYBUTYNIN CHLORIDE, Tablet, 5 mg, NDC 00603497521, Pedigree: AD52778_61, EXP: 5/20/2014; COENZYME Q-10, Capsule, 30 mg, NDC 00904501546, Pedigree: W002814, EXP: 6/7/2014.

What was recalled

CITALOPRAM Tablet, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 57664050788

Recalling firm
Aidapak Services, LLC
Origin
WA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-630-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Citalopram recalls

See all
Class II · Moderate risk Terminated

CITALOPRAM Tablets

Reason CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cardinal Healthcare D-0173-2024
Class III · Low risk Terminated

Citalopram Oral Solution

Reason Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint

PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-1696-40 D-0015-2021
Class II · Moderate risk Terminated

All citalopram Products

Reason Lack of Processing Controls

Reliable Rexall-A Compounding Pharmacy D-1090-2016
Class III · Low risk Terminated

Escitalopram Tablets USP 20 mg

Reason Labeling: Incorrect or Missing Lot and/or Expiration Date

Lupin Limited NDC 68180-136-01 D-1516-201
Class II · Moderate risk Terminated

Citalopram Hydrobromide active pharmaceutical ingredient packaged…

Reason Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-591-2015